BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 2319185)

  • 1. Relapses in paucibacillary leprosy after MDT--a clinical study.
    Grugni A; Nadkarni NJ; Kini MS; Mehta VR
    Int J Lepr Other Mycobact Dis; 1990 Mar; 58(1):19-24. PubMed ID: 2319185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses.
    Becx-Bleumink M
    Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):421-35. PubMed ID: 1474281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four-year follow-up results of a WHO-recommended multiple-drug regimen in paucibacillary leprosy patients in Malawi.
    Boerrigter G; Pönnighaus JM; Fine PE; Wilson RJ
    Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):255-61. PubMed ID: 2071983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical assessment of paucibacillary leprosy under multidrug therapy-three years followup study.
    Revankar CR; Karjivkar VG; Gurav VJ; Ganapati R
    Indian J Lepr; 1989 Jul; 61(3):355-9. PubMed ID: 2768883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy.
    Chen XS; Li WZ; Jiang C; Ye GY
    Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):379-87. PubMed ID: 10700911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixed duration MDT in paucibacillary leprosy (classical and modified).
    Nadkarni NJ; Grugni A; Kini MS
    Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):25-8. PubMed ID: 8326177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fixed duration MDT in paucibacillary leprosy.
    Mathai R; George S; Jacob M
    Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):237-41. PubMed ID: 2071980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New lesions after MDT in PB and MB leprosy: a report of 28 cases.
    Kar HK; Sharma P
    Indian J Lepr; 2008; 80(3):247-55. PubMed ID: 19432355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of relapse in leprosy after fixed-duration multidrug therapy.
    Li HY; Hu LF; Huang WB; Liu GC; Yuan LC; Jin Z; Li X; Li JL; Yang ZM
    Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):238-45. PubMed ID: 9251597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study on the effectiveness and safety of the WHO/MDT regimen in the northeast of Thailand; a prospective study, 1984-1996.
    Dasananjali K; Schreuder PA; Pirayavaraporn C
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):28-36. PubMed ID: 9207751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of leprosy patients with single lesions to MDT.
    Katoch K; Natrajan M; Yadav VS; Bhatia AS
    Acta Leprol; 1995; 9(3):133-7. PubMed ID: 7631584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
    Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
    Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of lepromin-negative borderline leprosy patients with low-dose Convit vaccine as an adjunct to multidrug therapy; a six-year follow-up study in Calcutta.
    Chaudhury S; Hajra SK; Mukerjee A; Saha B; Majumdar V; Chattapadhya D; Saha K
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):56-62. PubMed ID: 9207754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term follow-up results of 1 year MDT in MB leprosy patients treated with standard MDT + once a month Minocycline and Ofloxacin.
    Katoch K; Katoch VM; Natarajan M; Gupta UD; Sharma VD; Singh HB
    Indian J Lepr; 2008; 80(4):331-44. PubMed ID: 20329382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed resolution versus treatment failure in paucibacillary leprosy patients under six months fixed duration multidrug therapy.
    Job CK; Jayakumar J; Aschhoff M
    Indian J Lepr; 1997; 69(2):131-42. PubMed ID: 9290964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse rates in patients treated with dapsone monotherapy and combinations of dapsone and thiambutosine, thiacetazone, isoniazid and streptomycin in the pre-MDT era.
    Smith TC; Richardus JH
    Int J Lepr Other Mycobact Dis; 1994 Sep; 62(3):353-8. PubMed ID: 7525795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapses in multibacillary leprosy patients after multidrug therapy.
    Poojabylaiah M; Marne RB; Varikkodan R; Bala N; Dandakeri S; Martis J
    Lepr Rev; 2008 Sep; 79(3):320-4. PubMed ID: 19009982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative clinical trial in multibacillary leprosy with long-term relapse rates of four different multidrug regimens.
    Fajardo TT; Villahermosa L; Pardillo FE; Abalos RM; Burgos J; Dela Cruz E; Gelber RH
    Am J Trop Med Hyg; 2009 Aug; 81(2):330-4. PubMed ID: 19635893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients.
    Becx-Bleumink M
    Int J Lepr Other Mycobact Dis; 1991 Dec; 59(4):558-68. PubMed ID: 1802938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.